Ventoux Biosciences Secures U.S. Patent for Novel Therapy Targeting Dupuytren's Disease and Immune-Fibrotic Disorders

SAN DIEGO, Sept. 23, 2025 /PRNewswire/ -- Ventoux Biosciences, a biotechnology company developing disease-modifying therapies for fibrotic conditions, today announced the issuance of a U.S. patent covering methods for treating immune-fibrotic disorders, including Dupuytren's disease. The patent provides protection through 2044, further strengthening Ventoux's intellectual property portfolio and positioning the company to advance first-in-class therapies in an area of high unmet need.

Dupuytren's disease affects millions of people worldwide and is over four times more common than rheumatoid arthritis. Despite its prevalence and impact on hand function and quality of life, there are no approved disease-modifying therapies — only invasive or temporary interventions. Ventoux's approach seeks to change this paradigm by addressing the underlying biological pathways that drive fibrosis.

"This is a major milestone for Ventoux Biosciences," said Kurt Harrington, CEO and a patient living with Dupuytren's disease. "It validates our novel approach to targeting the drivers of fibrosis and underscores our commitment to bringing transformative therapies to patients. For too long, individuals with Dupuytren's and related conditions have had few options. We believe our platform has the potential to deliver meaningful, disease-modifying outcomes."

Ken Lipson, PhD, Chief Scientific Officer, added: "The patent highlights the innovative mechanism behind our therapy, which focuses on modulating key immune-fibrotic pathways involved in disease progression. With this protection in place, we are well positioned to advance our lead program toward preclinical proof-of-concept and ultimately clinical development."

"Dupuytren's disease remains a challenging condition for many patients, particularly given the lack of approved therapies that alter its underlying biology," said Dr. Gary M. Pess, MD, Senior Managing Partner and Medical Director at Central Jersey Hand Surgery and a leading expert in Dupuytren's treatment. "Ventoux Biosciences' recent patent and ongoing work are exciting because they move us closer to treatments that could modify disease progression rather than only treating contracture. This has the potential to change lives by preserving hand function, avoiding invasive interventions, and reducing burden over the long term."

Ventoux Biosciences' platform is designed to be applicable across multiple fibrotic disorders, many of which currently lack effective treatments. By focusing on the intersection of immune response and fibrosis, the company aims to unlock new therapeutic possibilities not only for Dupuytren's disease but for other chronic fibrotic conditions where patients face limited or no options today.

The patent issuance follows a period of growing recognition for Ventoux Biosciences, including industry awards for innovation and leadership in immune-fibrotic research. The company continues to advance its programs, strengthen its scientific partnerships, and prepare for the next phase of development.

About Ventoux Biosciences
Ventoux Biosciences is pioneering disease-modifying therapies for immune-fibrotic disorders, starting with Dupuytren's disease—one of the most common yet underserved fibrotic conditions. Led by a seasoned biopharma team, Ventoux is advancing a platform that addresses the underlying biological pathways that drive fibrosis with a goal of  delivering safe, effective, and lasting treatments. For more information, visit www.VentouxBio.com.

Media Contact:
Kurt Harrington
[email protected]
760-621-8303

SOURCE Ventoux Biosciences